250 related articles for article (PubMed ID: 31436251)
21. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
Kneuertz PJ; Carbone DP; D'Souza DM; Shilo K; Abdel-Rasoul M; Zhao W; Williams TM; Jones D; Merritt RE
Lung Cancer; 2020 May; 143():60-66. PubMed ID: 32208298
[TBL] [Abstract][Full Text] [Related]
22. Detection of MET Exon 14 Skipping Alterations in Lung Cancer Clinical Samples Using a PCR-Based Approach.
Sui JSY; Finn SP; Gray SG
Methods Mol Biol; 2021; 2279():145-155. PubMed ID: 33683691
[TBL] [Abstract][Full Text] [Related]
23. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.
Saffroy R; Fallet V; Girard N; Mazieres J; Sibilot DM; Lantuejoul S; Rouquette I; Thivolet-Bejui F; Vieira T; Antoine M; Cadranel J; Lemoine A; Wislez M
Oncotarget; 2017 Jun; 8(26):42428-42437. PubMed ID: 28418914
[TBL] [Abstract][Full Text] [Related]
24. Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer.
Xia Y; Jin R; Li M; Lan F; Zhu H; Yu Y; Miao D; Wang Q; Zhou Y; Selvaggi G; Ying S; Zhang J; Shen H; Le X; Li W
Cancer Lett; 2023 May; 561():216140. PubMed ID: 36948240
[TBL] [Abstract][Full Text] [Related]
25. Survival outcomes and prognostic factors of lung cancer patients with the
Gow CH; Hsieh MS; Chen YL; Liu YN; Wu SG; Shih JY
Front Oncol; 2023; 13():1113696. PubMed ID: 36969059
[TBL] [Abstract][Full Text] [Related]
26. Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy.
Hsieh MS; Lin MW; Lee YH
Lung Cancer; 2019 Nov; 137():76-84. PubMed ID: 31561203
[TBL] [Abstract][Full Text] [Related]
27. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
28. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
Suzawa K; Offin M; Lu D; Kurzatkowski C; Vojnic M; Smith RS; Sabari JK; Tai H; Mattar M; Khodos I; de Stanchina E; Rudin CM; Kris MG; Arcila ME; Lockwood WW; Drilon A; Ladanyi M; Somwar R
Clin Cancer Res; 2019 Feb; 25(4):1248-1260. PubMed ID: 30352902
[TBL] [Abstract][Full Text] [Related]
29. KRAS mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma.
Mehrad M; Roy S; LaFramboise WA; Petrosko P; Miller C; Incharoen P; Dacic S
Histopathology; 2018 Aug; 73(2):207-214. PubMed ID: 29489023
[TBL] [Abstract][Full Text] [Related]
30. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.
Wu C; Zhao C; Yang Y; He Y; Hou L; Li X; Gao G; Shi J; Ren S; Chu H; Zhou C; Zhang J; Schmid-Bindert G
J Thorac Oncol; 2015 May; 10(5):778-783. PubMed ID: 25629635
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
Sabari JK; Leonardi GC; Shu CA; Umeton R; Montecalvo J; Ni A; Chen R; Dienstag J; Mrad C; Bergagnini I; Lai WV; Offin M; Arbour KC; Plodkowski AJ; Halpenny DF; Paik PK; Li BT; Riely GJ; Kris MG; Rudin CM; Sholl LM; Nishino M; Hellmann MD; Rekhtman N; Awad MM; Drilon A
Ann Oncol; 2018 Oct; 29(10):2085-2091. PubMed ID: 30165371
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies.
Castiglione R; Alidousty C; Holz B; Wagener S; Baar T; Heydt C; Binot E; Zupp S; Kron A; Wolf J; Merkelbach-Bruse S; Reinhardt HC; Buettner R; Schultheis AM
Mod Pathol; 2019 May; 32(5):627-638. PubMed ID: 30459450
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
34. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
35. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
Guo R; Berry LD; Aisner DL; Sheren J; Boyle T; Bunn PA; Johnson BE; Kwiatkowski DJ; Drilon A; Sholl LM; Kris MG
J Thorac Oncol; 2019 Sep; 14(9):1666-1671. PubMed ID: 31228623
[TBL] [Abstract][Full Text] [Related]
36. MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population.
Lung J; Hung MS; Lin YC; Lee KF; Jiang YY; Huang SL; Fang YH; Lu MS; Lin CK; Yang TM; Lin PY; Hsieh MJ; Tsai YH
PLoS One; 2019; 14(8):e0220670. PubMed ID: 31369639
[TBL] [Abstract][Full Text] [Related]
37. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
Mazieres J; Vioix H; Pfeiffer BM; Campden RI; Chen Z; Heeg B; Cortot AB
Clin Lung Cancer; 2023 Sep; 24(6):483-497. PubMed ID: 37451931
[TBL] [Abstract][Full Text] [Related]
38. MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.
Wong SK; Alex D; Bosdet I; Hughesman C; Karsan A; Yip S; Ho C
Lung Cancer; 2021 Apr; 154():142-145. PubMed ID: 33667719
[TBL] [Abstract][Full Text] [Related]
39. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.
Mignard X; Ruppert AM; Antoine M; Vasseur J; Girard N; Mazières J; Moro-Sibilot D; Fallet V; Rabbe N; Thivolet-Bejui F; Rouquette I; Lantuejoul S; Cortot A; Saffroy R; Cadranel J; Lemoine A; Wislez M
J Thorac Oncol; 2018 Dec; 13(12):1962-1967. PubMed ID: 30149144
[TBL] [Abstract][Full Text] [Related]
40. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
Aggarwal C; Thompson JC; Black TA; Katz SI; Fan R; Yee SS; Chien AL; Evans TL; Bauml JM; Alley EW; Ciunci CA; Berman AT; Cohen RB; Lieberman DB; Majmundar KS; Savitch SL; Morrissette JJD; Hwang WT; Elenitoba-Johnson KSJ; Langer CJ; Carpenter EL
JAMA Oncol; 2019 Feb; 5(2):173-180. PubMed ID: 30325992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
